Low-dose rituximab in steroid-refractory chronic graft-versus-host disease

CONCLUSION: A low dose of rituximab is an available and cost-effective option for patients with steroid-refractory cGvHD.PMID:37972876 | DOI:10.1016/j.trim.2023.101959

Source: Transplant Immunology - November 16, 2023 Category: Transplant Surgery Authors: Perla Roc ío Colunga-Pedraza Luz Mar ía Barbosa Castillo Edgar Ulises Coronado Alejandro H éctor Alejandro Vaquera-Alfaro Ingrid Gabriela Lopez Reyna Julia E Colunga-Pedraza David G ómez Almaguer Source Type: research